TRACON Pharmaceuticals Company Profile (NASDAQ:TCON)

About TRACON Pharmaceuticals (NASDAQ:TCON)

TRACON Pharmaceuticals logoTRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TCON
  • CUSIP: N/A
  • Web: www.traconpharma.com
Capitalization:
  • Market Cap: $47.34 million
  • Outstanding Shares: 16,609,000
Average Prices:
  • 50 Day Moving Avg: $3.42
  • 200 Day Moving Avg: $4.48
  • 52 Week Range: $2.75 - $7.86
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.95
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.87 million
  • Price / Sales: 16.49
  • Book Value: $1.39 per share
  • Price / Book: 2.05
Profitability:
  • EBIDTA: ($26,510,000.00)
  • Net Margins: -750.91%
  • Return on Equity: -137.76%
  • Return on Assets: -72.55%
Debt:
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 2.77%
  • Quick Ratio: 2.77%
Misc:
  • Average Volume: 62,353 shs.
  • Beta: 2.77
  • Short Ratio: 4.03
 

Frequently Asked Questions for TRACON Pharmaceuticals (NASDAQ:TCON)

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The company earned $0.63 million during the quarter, compared to analysts' expectations of $0.92 million. TRACON Pharmaceuticals had a negative return on equity of 137.76% and a negative net margin of 750.91%. View TRACON Pharmaceuticals' Earnings History.

Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2017?

4 analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their predictions range from $10.00 to $15.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $13.00 in the next twelve months. View Analyst Ratings for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who owns TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (17.07%), Eventide Asset Management LLC (5.57%), Vanguard Group Inc. (1.11%), Candriam Luxembourg S.C.A. (0.88%), Renaissance Technologies LLC (0.39%) and Stifel Financial Corp (0.19%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, H Casey Logan, Jafco Super V3 Investment Limi, Peter W Sonsini and Ronald L Shazer. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Who bought TRACON Pharmaceuticals stock? Who is buying TRACON Pharmaceuticals stock?

TRACON Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Stifel Financial Corp and Geode Capital Management LLC. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy TRACON Pharmaceuticals stock?

Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TRACON Pharmaceuticals stock cost?

One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $2.85.

Analyst Ratings

Consensus Ratings for TRACON Pharmaceuticals (NASDAQ:TCON) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $13.00 (356.14% upside)

Analysts' Ratings History for TRACON Pharmaceuticals (NASDAQ:TCON)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/5/2017Stifel NicolausReiterated RatingBuy$14.00N/AView Rating Details
1/3/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2016Jefferies Group LLCInitiated CoverageBuy$10.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$15.00N/AView Rating Details
2/1/2016Oppenheimer Holdings Inc.Reiterated RatingOutperformN/AView Rating Details
10/8/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for TRACON Pharmaceuticals (NASDAQ:TCON)
Earnings by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Earnings History by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.47)($0.44)$0.92 million$0.63 millionViewN/AView Earnings Details
8/10/2016Q2($0.62)($0.68)$1.27 million$0.81 millionViewListenView Earnings Details
5/11/2016Q1($0.70)($0.54)$1.21 millionViewListenView Earnings Details
2/18/2016Q4($0.62)($0.91)$1.40 millionViewListenView Earnings Details
11/3/2015Q3($0.51)($0.53)$1.06 million$1.18 millionViewListenView Earnings Details
8/5/2015Q215($0.42)($0.24)$1.02 million$4.20 millionViewListenView Earnings Details
5/13/2015Q1($0.37)($0.50)$1.13 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)
2017 EPS Consensus Estimate: ($1.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.45)($0.45)($0.45)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.44)($0.44)($0.44)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TRACON Pharmaceuticals (NASDAQ:TCON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TRACON Pharmaceuticals (NASDAQ:TCON)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 24.03%
Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Institutional Ownership by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Insider Trades by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Peter W SonsiniMajor ShareholderBuy869,565$5.75$4,999,998.75View SEC Filing  
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44View SEC Filing  
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.00View SEC Filing  
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.00View SEC Filing  
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.68View SEC Filing  
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.48View SEC Filing  
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.00View SEC Filing  
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.00View SEC Filing  
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.00View SEC Filing  
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.97View SEC Filing  
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.52View SEC Filing  
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.00View SEC Filing  
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.32View SEC Filing  
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.64View SEC Filing  
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.00View SEC Filing  
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.00View SEC Filing  
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.00View SEC Filing  
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.00View SEC Filing  
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.00View SEC Filing  
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.00View SEC Filing  
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.88View SEC Filing  
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TRACON Pharmaceuticals (NASDAQ:TCON)
Latest Headlines for TRACON Pharmaceuticals (NASDAQ:TCON)
Source:
DateHeadline
americanbankingnews.com logo Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) to Announce -$0.53 EPS
www.americanbankingnews.com - May 26 at 7:36 AM
finance.yahoo.com logoTRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
finance.yahoo.com - May 26 at 7:35 AM
globenewswire.com logoTRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
globenewswire.com - May 24 at 8:56 AM
finance.yahoo.com logoTRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
finance.yahoo.com - May 24 at 8:56 AM
americanbankingnews.com logoFY2019 EPS Estimates for TRACON Pharmaceuticals Inc Raised by Jefferies Group (TCON)
www.americanbankingnews.com - May 15 at 10:02 AM
finance.yahoo.com logoEdited Transcript of TCON earnings conference call or presentation 10-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 2:13 AM
finance.yahoo.com logoTRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
finance.yahoo.com - May 12 at 2:13 AM
americanbankingnews.com logoTRACON Pharmaceuticals Inc (TCON) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 11 at 4:28 PM
finance.yahoo.com logoTRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 1:55 AM
finance.yahoo.com logoTracon reports 1Q loss
finance.yahoo.com - May 11 at 1:55 AM
finance.yahoo.com logoInvestor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 10:26 AM
americanbankingnews.com logoZacks: Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $920,000.00
www.americanbankingnews.com - May 4 at 10:56 AM
finance.yahoo.com logoTRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017
finance.yahoo.com - May 3 at 6:22 PM
americanbankingnews.com logoTRACON Pharmaceuticals (TCON) Earns Media Impact Rating of -0.06
www.americanbankingnews.com - May 1 at 4:42 PM
americanbankingnews.com logoTRACON Pharmaceuticals (TCON) Receives Daily News Impact Rating of -0.25
www.americanbankingnews.com - April 27 at 3:09 PM
americanbankingnews.com logoTRACON Pharmaceuticals (TCON) Given Daily Media Impact Rating of -0.07
www.americanbankingnews.com - April 19 at 9:47 AM
americanbankingnews.com logoTRACON Pharmaceuticals Inc (TCON) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 18 at 7:48 PM
americanbankingnews.com logoZacks: Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Post Quarterly Sales of $920,000.00
www.americanbankingnews.com - April 13 at 11:31 AM
americanbankingnews.com logoTRACON Pharmaceuticals Inc (TCON) Expected to Announce Earnings of -$0.47 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM
finance.yahoo.com logoTRACON Awarded ‘Most Innovative Trial Design’ for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards
finance.yahoo.com - April 10 at 7:39 PM
us.rd.yahoo.com logoTRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting
us.rd.yahoo.com - March 27 at 7:23 PM
rttnews.com logoTracon Pharmaceuticals Inc. (TCON) Is Rising On Aspire Capital Fund Agreement
www.rttnews.com - March 14 at 7:40 PM
finance.yahoo.com logoTRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
finance.yahoo.com - March 14 at 7:40 PM
finance.yahoo.com logo4:06 pm Tracon Pharmaceuticals announces $21 million common stock purchase agreement with Aspire Capital Fund
finance.yahoo.com - March 14 at 7:40 PM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
biz.yahoo.com - March 14 at 7:40 PM
finance.yahoo.com logoTRACON PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 7 at 8:01 PM
globenewswire.com logoTRACON Pharmaceuticals to Present at the 29th Annual Roth Conference - GlobeNewswire (press release)
globenewswire.com - March 6 at 7:23 PM
finance.yahoo.com logoTRACON Pharmaceuticals to Present at the 29th Annual Roth Conference
finance.yahoo.com - March 6 at 7:23 PM
finance.yahoo.com logoEdited Transcript of TCON earnings conference call or presentation 28-Feb-17 9:30pm GMT
finance.yahoo.com - March 1 at 11:24 PM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 1 at 9:35 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 1 at 9:35 AM
us.rd.yahoo.com logoTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - February 28 at 7:47 PM
biz.yahoo.com logoQ4 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - February 28 at 11:37 AM
finance.yahoo.com logoTRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017
finance.yahoo.com - February 21 at 4:47 PM
finance.yahoo.com logoTRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma
finance.yahoo.com - February 16 at 7:59 PM
investopedia.com logoTracon Tanks on Brain Cancer Drug Failure (TCON) - Investopedia
www.investopedia.com - February 13 at 8:39 PM
investopedia.com logoTracon Pharma Tanks on Brain Cancer Drug Failure
www.investopedia.com - February 13 at 3:38 PM
nasdaq.com logoHealth Care Sector Update for 02/10/2017: TCON,IMMU,SGEN,BSTG - Nasdaq
www.nasdaq.com - February 12 at 1:18 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 11 at 8:17 PM
nasdaq.com logoMid-Morning Market Update: Markets Open Higher; NVIDIA Beats Q4 Views
www.nasdaq.com - February 11 at 5:05 AM
us.rd.yahoo.com logoTRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma
us.rd.yahoo.com - February 10 at 5:57 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
biz.yahoo.com - February 9 at 6:04 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 9 at 6:04 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
biz.yahoo.com - January 10 at 1:19 AM
seekingalpha.com logoTracon Pharmaceuticals: ~$5 Biotech Stock With Plenty Of Catalysts In 2017
seekingalpha.com - January 7 at 3:51 AM
us.rd.yahoo.com logo8:05 am Tracon Pharmaceuticals receives special protocol assessment agreement from FDA for phase 3 clinical trial of TRC105 in Angiosarcoma
us.rd.yahoo.com - January 3 at 9:21 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - December 22 at 3:58 AM
finance.yahoo.com logoCoverage initiated on Tracon Pharmaceuticals by Jefferies
finance.yahoo.com - December 22 at 3:58 AM
biz.yahoo.com logoTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - December 14 at 5:46 AM

Social

Chart

TRACON Pharmaceuticals (TCON) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff